Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
about
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineAction of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levelsMeta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemiaSurvivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissuesSystematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.Harnessing Solute Carrier Transporters for Precision Oncology.Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma.Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.Survivin: A novel marker and potential therapeutic target for human angiosarcoma.Inhibitors of apoptosis: clinical implications in cancer.BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.YM155 inhibits topoisomerase function.Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.YM155 enhances docetaxel efficacy in ovarian cancer.Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL.Survivin as a novel target protein for reducing the proliferation of cancer cells.Prognostic role of survivin in patients with glioma.Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis.Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cellsmiR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathwayGrowth inhibition and chemo-radiosensitization of esophageal squamous cell carcinoma by survivin-shRNA lentivirus transfection
P2860
Q33731350-86C40B17-55FF-4C32-B056-7888AA21F6B1Q33764288-15E95411-9749-48B1-ACDA-081CA93782C9Q36276060-97AD53DA-2FBB-4EF9-9FA1-73E3112090A3Q36916428-5E4076BE-9678-410C-A788-DA32CCC5F044Q38729732-FB9340FA-8AE4-4006-B701-9ADA4DAD75BDQ39204754-2A58FB39-D831-4441-9771-E04089FB1F8AQ41200870-76C95E72-838F-4856-AC43-213AC55CE9A7Q41619667-BAECAAA9-D253-4A9E-8A11-A6302867FBD7Q47134049-3ABFFD40-18EC-4094-8E41-99CDEA09C537Q47607136-C247868B-51A5-4CA1-88E0-B29C41CA92CEQ48371625-56EA6694-48A7-4BC4-8A9A-D438561D425BQ48445482-88A3E453-7F25-42BE-8433-5EDE170455F0Q49218909-FB6153DD-21BA-441E-AA05-5CCA59AC9FE1Q51758973-57BA2D25-79A7-4268-A3CE-FF465992E6CDQ52595117-8B882591-8A90-4374-A1B6-5268FCF22841Q52724810-C7021D8D-6D04-4DC9-965B-858C498FF1B1Q55006767-05083499-118A-4711-AFD7-B33342067F70Q55044708-2FF0631C-168A-4057-BE02-14C74FAFB867Q55385538-1812FCC2-CEA4-4357-9B40-C7F157736477Q57493675-D8D0DE31-67B6-4B17-B1C4-521A4EE61079Q58706941-8026BB92-5365-426D-A5FE-559C56B54B23Q58794874-B11E5EFA-0E06-44D0-97B9-4F051B336F74
P2860
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@ast
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@en
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@nl
type
label
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@ast
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@en
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@nl
prefLabel
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@ast
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@en
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@nl
P2093
P2860
P1476
Phase II, multicenter, open-la ...... tive metastatic breast cancer.
@en
P2093
Anne Keating
Elaina Gartner
John Crown
Joyce Steinberg
Michael R Clemens
Oleg A Gladkov
Vladimir Vladimirov
P2860
P2888
P304
P356
10.1007/S10549-014-3238-6
P407
P577
2014-12-30T00:00:00Z
P5875
P6179
1020026554